Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DR. BOND who wrote (2888)	11/29/1997 12:56:00 PM
From: MisterED	Respond to of 23519

DB, I would like to remind the readers that most healthplans now accept DE as an insurable condition and will compensate for the use of Muse.

To: DR. BOND who wrote (2888)	11/30/1997 6:07:00 AM
From: Whipsaw	Read Replies (1) \| Respond to of 23519

Interesting Reflection! imsp008.netvigator.com. Thanks for posting this insightful Fortune article from March '97, the good old days when Vivus's chief rival is Pharmacia & Upjohn, which recently began marketing Caverject. It's good to remember that Muse has since virtually buried Caverject - a subject that's scarcely mentioned any more. This was quite an accomplishment for a little company with a single new product. Who says Vivus can not stand up to a big pharm?